Crinetics Pharmaceuticals CRNX 深 沪
已收盘 04-02 16:00:00 美东时间
37.23
+0.660
+1.80%
华盛通- 最 高37.29
- 今 开35.83
- 成交量 124.79万股
- 最 低 35.83
- 昨 收 36.57
- 总市值 38.98亿
- 52周最高 57.99
- 市盈率 静 --
- 换手率 1.19%
- 52周最低 25.83
- 委 比 -68.02%
- 总股本 1.05亿
- 历史最高 62.53
- 量 比 0.99
- 振 幅 3.99%
- 历史最低 10.63
- 每 手 1
- 风险率 7.81%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多新浪财经ESG：Crinetics Pharmaceuticals Inc. MSCI（明晟）ESG评级调降至BBB
新浪财经ESG评级中心提供包括资讯、报告、培训、咨询等在内的14项ESG服务，助力上市公司传播ESG理念，提升ESG可持续发展表现。点击查看【 ESG评级中...
03-24 10:18
Crinetics Pharma COO to step down
Crinetics Pharmaceuticals (CRNX) chief development and operating officer Jeff Knight will resign, effective around April 10, 2026. His responsibilities and team will be reassigned to other members of ...
03-24 03:54
Crinetics Chief Development and Operating Officer Jeff Knight to resign effective April 10, 2026
Crinetics Chief Development and Operating Officer Jeff Knight to resign effective April 10, 2026 Jeff Knight resigned as chief development and operating officer at Crinetics, effective on or about April 10, 2026. The departure was to pursue another opportunity, and it was not related to any disagree
03-23 21:04
美股大行评级 | 花旗：维持康菲石油"买入"评级！目标价从125美元升至135美元
今日重点评级关注：HC Wainwright & Co.：维持Helus Pharma"买入"评级，目标价从55美元升至95美元；HC Wainwright & Co.：维持Compass Pathways"买入"评级，目标价从40美元升至70美元
03-03 20:22
Citizens Maintains Market Outperform on Crinetics Pharmaceuticals, Lowers Price Target to $96
Citizens analyst Jonathan Wolleben maintains Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Market Outperform and lowers the price target from $105 to $96.
03-02 22:26
Crinetics Pharmaceuticals shares are trading lower. The company reported Q4 financial results.
Crinetics Pharmaceuticals shares are trading lower. The company reported Q4 fin...
02-28 00:32
财报速睇 | Crinetics Pharmaceuticals 2025财年Q4营收0.06亿美元，同比增长640.7%；归母净利润亏损1.23亿美元，同比亏损扩大52.4%
华盛资讯2月27日讯，Crinetics Pharmaceuticals公布2025财年Q4业绩，公司Q4营收0.06亿美元，同比增长640.7%，归母净利润亏损1.23亿美元，同比亏损扩大52.4%。
02-27 12:48
Crinetics Pharmaceuticals Earnings Report: Q4 Overview
Crinetics Pharmaceuticals (NASDAQ:CRNX) just disclosed its Q4 earnings on Thurs...
02-27 05:22
Earnings Scheduled For February 26, 2026
Companies Reporting Before The Bell • Enovis (NYSE:ENOV) is estimated to report...
02-26 19:11
Crinetics Pharmaceuticals Announces First Patient Dosed In BALANCE-CAH Phase 2/3 Trial Evaluating Investigational Candidate Atumelnant For Proposed Treatment Of Classic CAH In Children And Adolescents
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that the first patient has been dosed in the BALANCE-CAH Phase 2/3 trial evaluating investigational candidate atumelnant, a novel, once-daily oral
01-23 05:08
